ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53

Nature Chemical Biology

Volumn 8, Issue 7, 2012, Pages 646-654

  Sullivan, Kelly D ^a   Padilla Just, Nuria ^a   Henry, Ryan E ^a   Porter, Christopher C ^b   Kim, Jihye ^c   Tentler, John J ^c   Eckhardt, S Gail ^c   Tan, Aik Choon ^c   DeGregori, James ^b,d   Espinosa, Joaquín M ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; NUTLIN 3; PROTEIN P53; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; GENETIC ASSOCIATION; GENETIC SCREENING; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPHEROID CELL; SURVIVAL;

EID: 84862905519     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.965     Document Type: Article

References (49)

1. Vousden, K.H. & Prives, C. Blinded by the light: the growing complexity of p53. Cell 137, 413-431 (2009).
2. Brown, C.J., Lain, S., Verma, C.S., Fersht, A.R. & Lane, D.P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 9, 862-873 (2009).
3. Levesque, A.A. & Eastman, A. p53-based cancer therapies: is defective p53 the Achilles heel of the tumor? Carcinogenesis 28, 13-20 (2007).
4. Mandinova, A. & Lee, S.W. The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci. Transl. Med. 3, 64rv1 (2011).
5. Vassilev, L.T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
6. Tovar, C. et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. USA 103, 1888-1893 (2006).
7. Huang, B., Deo, D., Xia, M. & Vassilev, L.T. Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. Mol. Cancer Res. 7, 1497-1509 (2009).
8. París, R., Henry, R.E., Stephens, S.J., McBryde, M. & Espinosa, J.M. Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation. Cell Cycle 7, 2427-2433 (2008).
9. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007).
10. Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007).
11. el-Deiry, W.S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
12. σ is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1, 3-11 (1997).
13. Yu, J., Zhang, L., Hwang, P.M., Kinzler, K.W. & Vogelstein, B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7, 673-682 (2001).
14. Nakano, K. & Vousden, K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7, 683-694 (2001).
15. Wu, G.S. et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17, 141-143 (1997).
16. Müller, M. et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188, 2033-2045 (1998).
17. Vousden, K.H. & Lu, X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2, 594-604 (2002).
18. Sullivan, K.D., Gallant-Behm, C.L., Henry, R.E., Fraikin, J.L. & Espinosa, J.M. The p53 circuit board. Biochim. Biophys. Acta 1825, 229-244 (2012).
19. Bunz, F. et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263-269 (1999).
20. Kim, J. & Tan, A.C. BiNGS!SL-seq: a bioinformatics pipeline for the analysis and interpretation of deep sequencing genome-wide synthetic lethal screen. Methods Mol. Biol. 802, 389-398 (2012).
21. Porter, C.C. et al. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia published online; doi:10.1038/leu.2011.392 (13 January 2012).
22. Di Renzo, M.F. et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1, 147-154 (1995).
23. Takhar, A.S., Eremin, O. & Watson, S.A. The role of gastrin in colorectal carcinogenesis. Surgeon 2, 251-257 (2004).
24. Li, A., Varney, M.L. & Singh, R.K. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin. Cancer Res. 7, 3298-3304 (2001).
25. Sugai, T. et al. Frequent allelic imbalance at the ATM locus in DNA multiploid colorectal carcinomas. Oncogene 20, 6095-6101 (2001).
26. Hickson, I. et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64, 9152-9159 (2004).
27. Chou, T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446 (2010).
28. Friedrich, J., Seidel, C., Ebner, R. & Kunz-Schughart, L.A. Spheroid-based drug screen: considerations and practical approach. Nat. Protoc. 4, 309-324 (2009).
29. Olivero, M. et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br. J. Cancer 74, 1862-1868 (1996).
30. Yamazaki, S. et al. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab. Dispos. 36, 1267-1274 (2008).
31. Shaw, A.T. & Solomon, B. Targeting anaplastic lymphoma kinase in lung cancer. Clin. Cancer Res. 17, 2081-2086 (2011).
32. Sattler, M. et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 63, 5462-5469 (2003).
33. Hwang, C.I. et al. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc. Natl. Acad. Sci. USA 108, 14240-14245 (2011).
34. Zhang, Y., Xing, D. & Liu, L. PUMA promotes Bax translocation by both directly interacting with Bax and by competitive binding to Bcl-X L during UV-induced apoptosis. Mol. Biol. Cell 20, 3077-3087 (2009).
35. Chan, T.A., Hwang, P.M., Hermeking, H., Kinzler, K.W. & Vogelstein, B. Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev. 14, 1584-1588 (2000).
36. Henry, R.E., Andrysik, Z., Paris, R., Galbraith, M.D. & Espinosa, J.M.A. DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX. EMBO J. 31, 1266-1278 (2012).
37. Jiang, H. et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 23, 1895-1909 (2009).
38. Brummelkamp, T.R. et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol. 2, 202-206 (2006).
39. Biton, S. & Ashkenazi, A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling. Cell 145, 92-103 (2011).
40. Guo, Z., Kozlov, S., Lavin, M.F., Person, M.D. & Paull, T.T. ATM activation by oxidative stress. Science 330, 517-521 (2010).
41. Hadian, K. & Krappmann, D. Signals from the nucleus: activation of NF-κB by cytosolic ATM in the DNA damage response. Sci. Signal. 4, pe2 (2011).
42. Bykov, V.J. et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282-288 (2002).
43. Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10, 1321-1328 (2004).
44. Lavin, M.F. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat. Rev. Mol. Cell Biol. 9, 759-769 (2008).
45. Miyamoto, S. Nuclear initiated NF-êB signaling: NEMO and ATM take center stage. Cell Res. 21, 116-130 (2011).
46. Ding, J., Miao, Z.H., Meng, L.H. & Geng, M.Y. Emerging cancer therapeutic opportunities target DNA-repair systems. Trends Pharmacol. Sci. 27, 338-344 (2006).
47. Trusolino, L., Bertotti, A. & Comoglio, P.M. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11, 834-848 (2010).
48. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007).
49. Kwak, E.L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).